N-(1-tert-butylpyrazol-4-yl)-2-[3-chloro-4-(6-piperidin-4-yloxyquinolin-4-yl)oxyphenyl]acetamide
C29H32ClN5O3 — CID 171645468
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(1-tert-butylpyrazol-4-yl)-2-[3-chloro-4-(6-piperidin-4-yloxyquinolin-4-yl)oxyphenyl]acetamide
N-(1-tert-butylpyrazol-4-yl)-2-[3-chloro-4-(6-piperidin-4-yloxyquinolin-4-yl)oxyphenyl]acetamide (PubChem CID 171645468) has the molecular formula C29H32ClN5O3 and a molecular weight of 534.06 g/mol. Its IUPAC name is N-(1-tert-butylpyrazol-4-yl)-2-[3-chloro-4-(6-piperidin-4-yloxyquinolin-4-yl)oxyphenyl]acetamide.
Molecular Properties
| Compound Name | N-(1-tert-butylpyrazol-4-yl)-2-[3-chloro-4-(6-piperidin-4-yloxyquinolin-4-yl)oxyphenyl]acetamide |
|---|---|
| PubChem CID | 171645468 |
| Molecular Formula | C29H32ClN5O3 |
| Molecular Weight | 534.06 g/mol |
| Exact Mass | 533.22 |
| IUPAC Name | N-(1-tert-butylpyrazol-4-yl)-2-[3-chloro-4-(6-piperidin-4-yloxyquinolin-4-yl)oxyphenyl]acetamide |
| SMILES | CC(C)(C)n1cc(NC(=O)Cc2ccc(Oc3ccnc4ccc(OC5CCNCC5)cc34)c(Cl)c2)cn1 |
| InChI | InChI=1S/C29H32ClN5O3/c1-29(2,3)35-18-20(17-33-35)34-28(36)15-19-4-7-27(24(30)14-19)38-26-10-13-32-25-6-5-22(16-23(25)26)37-21-8-11-31-12-9-21/h4-7,10,13-14,16-18,21,31H,8-9,11-12,15H2,1-3H3,(H,34,36) |
| InChIKey | CGGARENAGFGSHC-UHFFFAOYSA-N |
| XLogP | 5.94 |
| TPSA | 90.30 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 38 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 534.06 |
| LogP ≤ 5 | 5.94 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171645468 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.